iXensor's CDMO New Business Model Accelerates Next-Generation At-Home Testing and...

撰文GlobalBio & Investment
日期2023-12-01
iXensor's CDMO New Business Model Accelerates Next-Generation At-Home Testing and POCT Product Development
【Editor's Choice | Taiwan's Medical Device】
iXensor's CDMO New Business Model Accelerates Next-Generation At-Home Testing and POCT Product Development
 
iXensor (6734. TWO), established in 2012, is the world's first mobile healthcare company to turn smartphones into lab-grade medical diagnostic devices for self-testing, and has successfully introduced its own brand to the market.
 
Taking advantage of the opportunities brought by the COVID-19 pandemic, iXensor, which had an early strategic focus on telemedicine, started to experience positive developments in 2022. These developments included technology licensing and partner co-developments with Rohto Pharmaceutical, as well as a strategic partnership with Innova Medical Group. Furthermore, iXensor expanded its business model from self-branding to CDMO services.
 
Find more news and insights from #GlobalBio's: https://lnkd.in/epg-qVJb

#MedicalTaiwan2023 #CDMO #POCT #testing #telemedicine #iXensor #安盛生科